You are here: Industry Insights > NASH

News List

Hanmi Pharmaceutical expects U.S. FDA approval for 2 new drugs prnasia
January 19, 2021
Hanmi Pharmaceutical Co., Ltd. plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in ...
Metacrine Reports Positive Results from Phase 1 Trial of MET642 for NASH americanpharmaceuticalreview
January 06, 2021
Metacrine has reported preliminary results from its Phase 1 trial of MET642, a farnesoid X receptor (FXR) agonist being developed for the treatment of non-alcoholic steatohepatitis (NASH) and inflammatory bowel disease.
HemoShear Identifies Novel Drug Target to Treat NASH in Partnership with Takeda americanpharmaceuticalreview
December 31, 2020
HemoShear Therapeutics has achieved a research milestone in its discovery and development collaboration with Takeda Pharmaceutical to advance its first nonalcoholic steatohepatitis (NASH) target into Takeda's discovery portfolio.
First Subject Dosed with Gannex's FXR Agonist ASC42 in a U.S. Phase I Trial prnasia
December 28, 2020
Gannex announces today dosing of first subject with its NASH drug candidate ASC42, a Farnesoid X Receptor (FXR) agonist, in a U.S. Phase I Trial.
FDA accepts Hepion’s IND application for CRV431 to treat Covid-19 pharmaceutical-business-review
December 28, 2020
The US Food and Drug Administration (FDA) has accepted Hepion Pharmaceuticals’ investigational new drug (IND) application for its CRV431, a novel cyclophilin inhibitor, to treat Covid-19.
Overweight and Obese Subjects Dosed with ASC41 Tablets in a Phase Ib Trial prnasia
December 22, 2020
Gannex announces today dosing of overweight and obese subjects in a Phase Ib trial of ASC41, an oral tablet, liver-targeted prodrug and its active moiety (ASC41-A), a selective thyroid hormone receptor beta (THR-β) agonist.
Oramed Initiates NASH Trial of Oral Insulin americanpharmaceuticalreview
December 03, 2020
Oramed Pharmaceuticals has screened the first patients in a global trial of its oral insulin capsule ORMD-0801 for the treatment of Nonalcoholic steatohepatitis (NASH).
Successive drug launches will drive growth of NASH market in seven major markets: GlobalData expresspharma
November 24, 2020
The NASH market will undergo a very rapid growth, at a compound annual growth rate (CAGR) of 68.8 per cent from 2019 to 2029.
ASC40 (TVB-2640) Phase 2 NASH Trial Completed Patient Enrollment in China prnasia
November 19, 2020
Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. and Sagimet Biosciences Inc. jointly announced today that they have completed patient enrollment in the ASC40 (TVB-2640) Phase 2 NASH trial in China.
Gilead and Novo Nordisk’s NASH trial meets primary endpoint pharmatimes
November 18, 2020
Gilead and Novo Nordisk have announced that a phase II proof-of-concept trial evaluating combination treatments for non-alcoholic steatohepatitis (NASH) met its primary endpoint.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page